Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $54.82 Average Target Price from Analysts

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has been assigned an average rating of “Buy” from the fourteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $54.8182.

XENE has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Wells Fargo & Company increased their target price on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, December 11th. Bloom Burton raised Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, October 7th. Royal Bank Of Canada upped their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th.

Insider Transactions at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the transaction, the chief executive officer owned 6,000 shares in the company, valued at approximately $266,580. The trade was a 86.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 65,302 shares of company stock valued at $2,924,128. Company insiders own 4.07% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after acquiring an additional 1,435,096 shares in the last quarter. Braidwell LP increased its position in shares of Xenon Pharmaceuticals by 33.0% during the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock valued at $112,837,000 after purchasing an additional 895,154 shares during the period. Commodore Capital LP raised its stake in shares of Xenon Pharmaceuticals by 30.1% in the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after purchasing an additional 700,000 shares in the last quarter. Vestal Point Capital LP lifted its position in Xenon Pharmaceuticals by 53.8% in the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after purchasing an additional 700,000 shares during the period. Finally, Holocene Advisors LP boosted its stake in Xenon Pharmaceuticals by 9.2% during the third quarter. Holocene Advisors LP now owns 1,976,553 shares of the biopharmaceutical company’s stock worth $79,359,000 after buying an additional 167,078 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Trading Down 1.0%

Shares of Xenon Pharmaceuticals stock opened at $41.95 on Monday. The firm has a fifty day simple moving average of $43.02 and a 200-day simple moving average of $39.48. The stock has a market capitalization of $3.24 billion, a price-to-earnings ratio of -10.78 and a beta of 0.97. Xenon Pharmaceuticals has a 1-year low of $26.74 and a 1-year high of $46.60.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.01. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the business earned ($0.81) earnings per share. As a group, research analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.